New vaccine update bumps BioNTech and Pfizer upwards

21 August 2020

Shares in German company BioNTech (Nasdaq: BNTX) and US pharma giant Pfizer (NYSE: PFE) are both set to open Friday’s training with significant gains after the latest update on their COVID-19 vaccine.

They shared additional Phase I safety and immunogenicity data from their ongoing US study of the BNT162 mRNA-based vaccine program against SARS-CoV-2, which has advanced into Phase II/III testing.

At seven days after a second dose of 30ug, BNT162b2 elicited SARS-CoV-2–neutralizing geometric mean titers (GMTs) in younger adults aged from 18 to 55 years that were 3.8 times the GMT of a panel of 38 sera of SARS-CoV-2 convalescent patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK